Barriers to Axsome AXS-07 migraine treatment beyond FDA approval, its
Central nervous system (CNS) specialist Axsome Therapeutics (Nasdaq: AXSM) expects to receive a full response letter (CRL) from the FDA due to chemistry, manufacturing and control (CMS) issues recently revealed during of the…